Zleepax is a New York-based pharmaceutical company devoted to improving nighttime and daytime quality of life for people with insomnia.
Our patent-pending compound, ZLX-1, has demonstrated efficacy without the unwanted side effect associated with traditional hypnotics, identified as the No. 1 problem with current sleep medication.
As chief executive officer at Blake Insomnia, I am responsible for piloting our company safely towards the launch of our first formulation, ZLX-1.
To complete Phase II, Blake Insomnia is ready to issue new shares to raise a one digit USD million amount, considerably less than average for new chemical entities, because ZLX-1 is based on a wellknown, safe agent that is already proven to enhance sleep8.
In addition to overseeing the new share issuance and preparations for clinical testing, I am currently transitioning our organization from its current structure to a more mature organizational form. This includes establishing a fully fledged board of directors, appointing a science advisory board and hiring a project manager.
The ZLX-1 is expected to reach the market via a licensing, sale to or partnership with a larger pharmaceutical company.
|Phase I||Phase II||Phase III||Phase IV|
|Estimated Time||1 Year||1–2 years||1–4 years||+1 year|
|Process||Studies safety||Studies efﬁcacy||Studies safety, efﬁcacy and dosing||Studies long-term efﬁcacy & cost-effectiveness|